Sangiovanni Timothy J. 4

What Happened

• Timothy J. Sangiovanni, SVP Finance & Corporate Controller of Zevra Therapeutics (ZVRA), sold 1,750 shares in an open‑market transaction on Jan 30, 2026 for a weighted average price of $8.82 per share, totaling $15,442.
• In connection with RSU vesting, the filing also shows conversions/exercises of restricted stock units into common shares on Jan 30 (6,333 shares) and Jan 31, 2026 (11,666 shares). Corresponding entries show disposals at $0.00 for 6,333 and 11,666 shares (reported as derivative dispositions).

Key Details

• Transaction dates & prices: Jan 30, 2026 — open‑market sale of 1,750 shares at weighted avg $8.82 (trade prices ranged $8.62–$8.995); Jan 30 & Jan 31, 2026 — RSU conversions of 6,333 and 11,666 shares (reported as derivative exercises/conversions, code M).
• Proceeds: Open‑market sale netted $15,442 (weighted average price reported).
• Shares owned after transaction: Not specified in the excerpt provided.
• Notable footnotes: F1 clarifies each RSU = right to one common share; F4/F5 describe vesting/settlement schedule (one‑third vested/settled on Jan 30/Jan 31 with remaining tranches per schedule); F2 notes a 10b5‑1 trading plan adopted 3/28/2025; F3 explains the open‑market sale was executed in multiple trades (prices ranged $8.62–$8.995).
• Timeliness: Filing date 2026‑02‑02 for transactions dated Jan 30–31, 2026 — the filing appears to be timely.

Context

• The derivative (M) entries correspond to RSUs vesting and converting into shares. The $0.00 disposal lines commonly reflect shares surrendered/settled in connection with the vesting (e.g., withholding or settlement mechanics); the footnotes state the RSUs vested and were settled on the listed dates.
• The 1,750‑share sale was executed under a pre‑arranged 10b5‑1 plan (per footnote), which is a preplanned trading arrangement rather than an ad hoc open‑market sale.